Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma

M. L. Donato, R. E. Champlin, K. W. Van Besien, M. Korbling, F. Cabanillas, P. Anderlini, J. G. Gajewski, J. Lauppe, A. Durett, B. Andersson, S. Giralt, I. Khouri, F. Hagemeister, J. E. Romaguera, A. Sarris, P. McLaughlin, A. Younes, C. Ippoliti, D. A. Blamble, J. HesterA. Gee, M. A. Rodriguez

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


We studied 36 patients with non-Hodgkin's lymphoma to evaluate the stem cell yield following recovery from intensive dose ifosfamide and etoposide given as mobilization chemotherapy. We also assessed the toxicity of the regimen and engraftment kinetics. All patients had intermediate grade lymphoma and had either failed to achieve a complete remission to induction chemotherapy or had relapsed. Patients received ifosfamide 10 g/m2 IV total dose given over 72 hours, etoposide 150 mg/m2 IV every 12 hours for 6 doses and G-CSF 10 μg/kg/d. Thirty-four patients went on to receive high-dose chemotherapy with BEAM or with CVP and BEAM. A median of 2 (1-10) apheresis was required to reach the target CD34+ count of > 4 x 106/kg. A median of 13.1 CD34+ cells/kg (4.1-148) was obtained. Toxicity was limited to mucositis in 3 patients, transient confusion and transient rise in liver function tests in 3 and 2 patients respectively. The median time to engraftment was 10 days (8-17) for all the patients undergoing high-dose chemotherapy. The regimen of intensive dose ifosfamide and etoposide along with G-CSF is well tolerated and in this group of patients has lead to successful stem cell harvests and sustained engraftment.

Original languageEnglish (US)
Pages (from-to)317-324
Number of pages8
JournalLeukemia and Lymphoma
Issue number3-4
StatePublished - 1999


  • Etoposide stem cells
  • Ifosfamide
  • Lymphoma
  • Mobilization

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma'. Together they form a unique fingerprint.

Cite this